Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | AGXT | P21549 | 11/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 10/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19250953 | 0.84 | LMNA (0.53) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL1793682 | 0.82 | LMNA (0.78) | LMNAMPOHCRTR1HCRTR2GLS | |
| Hydrochloric Acid SCHEMBL5656437 | 0.81 | LMNA (0.76) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL14074977 | 0.81 | LMNA (0.50) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL19251351 | 0.81 | LMNA (0.50) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL5224259 | 0.79 | LMNA (0.62) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL15602026 | 0.79 | LMNA (0.57) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL17629558 | 0.79 | LMNA (0.57) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL27778663 | 0.79 | LMNA (0.57) | LMNAMPOHCRTR1HCRTR2GLS | |
| SCHEMBL327273 | 0.79 | LMNA (0.57) | LMNAMPOHCRTR1HCRTR2GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | LMNA 3712/4885AGXT 1676/4885MPO 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.